Envision Pharma’s Private Equity Owners Weigh Sale
(Bloomberg) -- Envision Pharma Group's private equity owners are considering a sale of the medical communications company in a deal that could value the business at more than $500 million, people with knowledge of the matter said.
Ardian SAS and GHO Capital are speaking with advisers about the potential divestment after receiving approaches from suitors, according to the people, who asked not to be identified because the information is private. They could kick off a sale process later this year, the people said.
The health-care industry has been a bright spot for dealmaking at time when the coronavirus has been hampering mergers and acquisitions globally. U.S. buyout firm Warburg Pincus said last week it bought a stake in French biotechnology company Polyplus-Transfection SA. In April, Canada's Onex Corp. said it would acquire medical staffing provider Independent Clinical Services.
No final decisions have been made, and Envision Pharma's owners could decide to keep the business for longer, the people said. A spokesperson for Ardian declined to comment, while representatives for GHO and Envision didn't immediately respond to requests for comment.
Envision Pharma, founded in 2001, helps medical affairs teams manage projects, publications and data. It has 10 offices globally and employs around 450 staff, according to Ardian's website.
Paris-based Ardian and health care-focused GHO acquired the company from Halifax Group in 2016.
©2020 Bloomberg L.P.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
